1.上海中医药大学附属市中医医院(上海 200071)
朱文,男,硕士研究生,主要从事中医药防治心血管疾病临床与研究工作
冯其茂,主任医师,硕士研究生导师; E-mail:fenqimao@126.com
扫 描 看 全 文
朱文,谢凤群,程洁,等.基于“心与小肠相表里”理论探讨肠道菌群与高血压的关系[J].上海中医药杂志,2023,57(8):57-62.
ZHU Wen,XIE Fengqun,CHENG Jie,et al.Explore relationship between gut microbiota and hypertension based on the theory of “the heart and small intestine forming an exterior and interior relationship”[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):57-62.
朱文,谢凤群,程洁,等.基于“心与小肠相表里”理论探讨肠道菌群与高血压的关系[J].上海中医药杂志,2023,57(8):57-62. DOI: 10.16305/j.1007-1334.2023.2209087.
ZHU Wen,XIE Fengqun,CHENG Jie,et al.Explore relationship between gut microbiota and hypertension based on the theory of “the heart and small intestine forming an exterior and interior relationship”[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):57-62. DOI: 10.16305/j.1007-1334.2023.2209087.
肠道菌群是影响高血压发生发展的重要因素,中医学认为心与小肠在经络上相互联系,生理上相互配合,病理上相互影响,即“心与小肠相表里”。基于“心与小肠相表里”理论,结合相关文献,探讨肠道菌群与高血压的相关性,以及中药通过调节肠道菌群对高血压的防治作用,以期为高血压的临床诊疗提供思路。
The gut microbiota is an important factor in the development of hypertension. According to traditional Chinese medicine theory, the heart and small intestine are interconnected in meridians, cooperate with each other physiologically, and influence each other pathologically, i.e., “the heart and small intestine are exteriorly and interiorly interrelated”. Based on the theory of “the heart and small intestine forming an exterior and interior relationship” and review of relevant literature, the correlation between gut microbiota and hypertension, and the preventive and therapeutic effects of traditional Chinese herbal medicines on hypertension through regulating gut microbiota were discussed, with a view to providing ideas for the clinical treatment of hypertension.
高血压肠道菌群心与小肠相表里中药中医药疗法
hypertensiongut microbiotathe heart and small intestine forming an exterior and interior relationshiptraditional Chinese herbal medicinetraditional Chinese medicine therapy
《中国心血管健康与疾病报告2020》编写组. 《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究,2021, 19(7): 582-590.
罗永芬. 腧穴学[M]. 上海:上海科学技术出版社,1996: 75.
孙广仁. 中医基础理论[M]. 北京:中国中医药出版社,2002: 115.
王清海. 论高血压的中医概念与病名[J]. 中华中医药学刊,2008, 26(11): 2321-2323.
王清海,陶军. 创新中医脉胀理论,推动高血压中西医结合防治[J]. 中华高血压杂志,2018, 26(2): 123-125.
李广浩,沈琳,周端. 研读《内经》含英咀华——高血压病中医病名、病位与病机理论初探[J]. 浙江中医药大学学报,2014, 38(2): 134-136.
董丽,徐厚平,罗钢,等. 从“脉胀”认识高血压病[J]. 中医杂志,2018, 59(15): 1288-1290.
邵加庆. 代谢性疾病防控的新大陆——肠道菌群[J]. 医学研究生学报,2016, 29(1): 16-20.
SUGAHARA H, ODAMAKI T, FUKUDA S, et al. Probiotic Bifidobacterium longum alters gut luminal metabolism through modification of the gut microbial community[J]. Sci Rep, 2015, 5: 13548.
JrHILLS R D, PONTEFRACT B A, MISHCON H R, et al. Gut microbiome: profound implications for diet and disease[J]. Nutrients, 2019, 11(7) :1613.
VAN HECKE T, DE VRIEZE J, BOON N, et al. Combined consumption of beef-based cooked mince and sucrose stimulates oxidative stress, cardiac hypertrophy, and colonic outgrowth of desulfovibrionaceae in rats[J]. Mol Nutr Food Res, 2019, 63(2): e1800962.
PALMU J, SALOSENSAARI A, HAVULINNA A S, et al. Association between the gut microbiota and blood pressure in a population cohort of 6953 individuals[J]. J Am Heart Assoc, 2020, 9(15): e016641.
YAN Q, GU Y, LI X, et al. Alterations of the gut microbiome in hypertension[J]. Front Cell Infect Microbiol, 2017, 7: 381.
VIEIRA-ROCHA M S, SOUSA J B, RODRIGUEZ-RODRIGUEZ P, et al. Insights into sympathetic nervous system and GPCR interplay in fetal programming of hypertension: a bridge for new pharmacological strategies[J]. Drug Discov Today, 2020, 25(4): 739-747.
胡娟,汪星辉,高杉,等. 肠道菌群在心血管疾病中的作用及其机制研究进展[J]. 中国药理学通报,2019, 35(11): 1496-1500.
TAN J K, MCKENZIE C, MARIÑO E, et al. Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation[J]. Annu Rev Immunol, 2017, 35(1): 371-402.
PLUZNICK J L, PROTZKO R J, GEVORGYAN H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation[J]. Proc Natl Acad Sci USA, 2013, 110(11): 4410-4415.
PLUZNICK J. A novel SCFA receptor, the microbiota, and blood pressure regulation[J]. Gut microbes, 2014, 5(2): 202-207.
XIE G, YAN A, LIN P, et al. Trimethylamine N-oxide-a marker for atherosclerotic vascular disease[J]. Rev Cardiovasc Med, 2021, 22(3): 787-797.
GE X, ZHENG L, ZHUANG R, et al. The gut microbial metabolite trimethylamine N-oxide and hypertension risk:a systematic review and dose-response meta-analysis[J]. Adv Nutr, 2020, 11(1): 66-76.
TEFT W A, MORSE B L, LEAKE B F, et al. Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters[J]. Mol Pharm, 2017, 14(1): 310-318.
DURGAN D J, GANESH B P, COPE J L, et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension[J]. Hypertension, 2016, 67(2): 469-474.
罗雅亭,程如越,梁惠菁,等. 高脂饮食对小鼠糖、脂代谢及肠道菌群结构的影响[J].营养学报,2020, 42(5): 458-464.
GRÜNER N, MATTNER J. Bile acids and microbiota: multifaceted and versatile regulators of the liver-gut axis[J]. Int J Mol Sci, 2021, 22(3): 1397-1397.
JOYCE S A, GAHAN C G. Disease-associated changes in bile acid profiles and links to altered gut microbiota[J]. Dig Dis, 2017, 35(3): 169-177.
PARKS D J, BLANCHARD S G, BLEDSOE R K, et al. Bile acids: natural ligands for an orphan nuclear receptor[J]. Science, 1999, 284(5418): 1365-1368.
BÜHLER H, PERSCHEL F H, FITZNER R, et al. Endogenous inhibitors of 11 beta-OHSD: existence and possible significance[J]. Steroids, 1994, 59(2): 131-135.
YAU M, HAIDER S, KHATTAB A, et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency[J]. Proc Natl Acad Sci U S A, 2017, 114(52): E11248-E11256.
MADHUR M S, LOB H E, MCCANN L A, et al. Interleukin 17 promotes angiotensin Ⅱ-induced hypertension and vascular dysfunction[J]. Hypertension, 2010, 55(2): 500-507.
ROBLES-VERA I, TORAL M, DE LA VISITACIÓN N, et al. The probiotic lactobacillus fermentum prevents dysbiosis and vascular oxidative stress in rats with hypertension induced by chronic nitric oxide blockade[J]. Mol Nutr Food Res, 2018, 62(19): 1-13.
严培玲,罗永建,刘海丰,等. 老年高血压患者肠道菌群变化及其与血清炎症指标的相关性[J]. 中国老年学杂志,2020, 40(18): 3871-3874.
KIM S, GOEL R, KUMAR A, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure[J]. Clinical science, 2018, 132(6): 701-718.
VAN BEUSECUM J P, BARBARO N R, MCDOWELL Z, et al. High salt activates CD11c+ antigen-presenting cells via SGK (serum glucocorticoid kinase) 1 to promote renal inflammation and salt-sensitive hypertension[J]. Hypertension, 2019, 74(3): 555-563.
WILCK N,MATUS M G,KEARNEY S M,et al. Salt-responsive gut commensal modulates TH17 axis and disease[J]. Nature, 2017, 551 (7682): 585-589.
DABKE K, HENDRICK G, DEVKOTA S. The gut microbiome and metabolic syndrome[J]. J Clin Invest, 2019, 129(10): 4050-4057.
PICKARD J M, ZENG M Y, CARUSO R, et al. Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease[J]. Immunol Rev, 2017, 279(1): 70-89.
VALLIANOU N G, GELADARI E, KOUNATIDIS D. Microbiome and hypertension: where are we now?[J]. J Cardiovasc Med, 2020, 21(2): 83-88.
BARROWS I R, RAMEZANI A, RAJ D S. Inflammation, immunity, and oxidative stress in hypertension-partners in crime?[J]. Adv Chronic Kidney Dis, 2019, 26(2): 122-130.
TORAL M, ROBLES-VERA I, DE LA VISITACIÓN N, et al. Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats[J]. Acta Physiol, 2019, 227(1): e13285.
KARBACH S H, SCHÖNFELDER T, BRANDÃO I, et al. Gut microbiota promote angiotensin Ⅱ-induced arterial hypertension and vascular dysfunction[J]. J Am Heart Assoc, 2016, 5(9): e003698.
SANTISTEBAN M M, QI Y, ZUBCEVIC J, et al. Hypertension-linked pathophysiological alterations in the gut[J]. Circ Res, 2017, 120(2): 312-323.
LA SALVIA S, MUSANTE L, LANNIGAN J, et al. T cell-derived extracellular vesicles are elevated in essential HTN[J]. Am J Physiol Renal Physiol, 2020, 319(5): F868-F875.
BARBARO N R , FOSS J D, KR YSHTAL D O, et al. Dendritic cell amiloride-sensitive channels mediate sodium-induced inflammation and hypertension[J]. Cell Rep, 2017, 21(4): 1009-1020.
ELIJOVICH F, LAFFER C L, SAHINOZ M, et al. The gut microbiome, inflammation, and salt-sensitive hypertension[J]. Curr Hypertens Rep, 2020, 22(10): 79.
赵君,杜金行,汪国梁,等. 中药治疗原发性高血压随机对照试验的Meta分析[J]. 中华中医药杂志,2018, 33(6): 922-926.
XU J, CHEN H B, LI S L, et al. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota[J]. Med Res Rev, 2017, 37(5): 1140-1185.
吴山永,姜宁华,石彦波,等. 小柴胡汤联合厄贝沙坦对高血压患者肠道菌群及脂代谢影响[J]. 中华中医药学刊,2022, 40(1): 169-172.
齐容. 车前子粗多糖胶囊对老年高血压患者肠道微生态环境的影响[D]. 兰州:甘肃中医药大学,2017.
王海利,郅杰超. 中药治疗对痰瘀互结型初发高血压患者血、尿代谢组学、肠道微生态及睡眠质量的影响研究[J]. 世界睡眠医学杂志,2021, 8(2): 230-232.
刘巍,熊兴江,王阶. 高血压病的汉方证治探讨[J]. 上海中医药大学学报,2013, 27(4): 86-91.
马晓聪,熊兴江,莫毅,等. 基于16S rDNA测序技术的自发性高血压大鼠肠道菌群结构变化及中药干预作用[J]. 中华中医药学刊,2020, 38(8): 71-74,266.
苗婷婷. 三黄泻心汤研究进展[J]. 湖南中医杂志,2016, 32(3): 190-192.
赵珊珊,杨梦琦,谢人明,等. 三黄泻心汤对麻醉大鼠血压的影响[J]. 中国药理学与毒理学杂志,2019, 33(9): 748-749.
WU J, NAKASHIMA S, NAKAMURA S, et al. Effects of Sanoshashinto on left ventricular hypertrophy and gut microbiota in spontaneously hypertensive rats[J]. J Nat Med, 2020, 74(2): 482-486.
YU X, ZHANG X, JIN H, et al. Zhengganxifeng Decoction affects gut microbiota and reduces blood pressure via renin-angiotensin system[J]. Biol Pharm Bull, 2019, 42(9): 1482-1490.
周秀,刘静,李家富. 槲皮素对自发性高血压大鼠血压、肠道菌群及心室重构的影响及机制研究[J]. 天然产物研究与开发,2020, 32(9): 1449-1455.
张光远,吴晓利,张志明,等. 大豆皂苷对高盐饮食小鼠血压和肠道菌群的影响[J]. 中国食物与营养,2019, 25(4): 17-21, 30.
王帅,石燕红,王瑞,等. 中药前胡中香豆素类化学成分及其分析方法、药理作用研究进展[J]. 上海中医药杂志,2022, 56(9): 89-99.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构